Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel–Lindau disease

Tsai, Fang-Yi; Lau, Ling Ing; Chen, Shih‐Jen; Lee, Fenq-Lih; Lee, Shui‐Mei

doi:10.1016/j.jcma.2013.09.001

Cited by 14 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,29,49,66,140,151,154,201 In only seven of these cases was a good response observed (54% success). 29, 151, 154 Compared to retinal capillary hemangiomas without VHL, there is less scientific evidence to support the effectiveness of PDT in treating VHL.…”

Section: Von Hippel-lindau Angiomatosismentioning

confidence: 97%

See 1 more Smart Citation

Clinical use of photodynamic therapy in ocular tumors

Çerman

Çekıç

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

Section: Von Hippel-lindau Angiomatosismentioning

confidence: 97%

“…Bakri et al, 20 Bhattacharjee et al, 29 Chen et al, 49 Fong et al, 66 Papastefanou et al, 140 RodriguesColeman et al, 151 Sachdeva et al, 154 Tsai et al 201 …”

Section: Circumscribed Choroidal Hemangiomamentioning

confidence: 99%

Clinical use of photodynamic therapy in ocular tumors

Çerman

Çekıç

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

“…According to Tsai et al, corticosteroids seem to be more effective in reducing exudation than bevacizumab. 155 Walker et al described a VHL patient with rebound neovascularization after intravitreal bevacizumab injection, again without effect on tumor volume. 156 Also, the systemic use of bevacizumab has been tested.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

<p>Von Hippel-Lindau Disease: Current Challenges and Future Prospects</p>

Gläsker¹,

Vergauwen²,

Koch³

et al. 2020

OTT

View full text Add to dashboard Cite

Understanding of molecular mechanisms of tumor growth has an increasing impact on the development of diagnostics and targeted therapy of human neoplasia. In this review, we summarize the current knowledge on molecular mechanisms and their clinical implications in von Hippel-Lindau (VHL) disease. This autosomal dominant tumor syndrome usually manifests in young adulthood and predisposes affected patients to the development of benign and malignant tumors of different organ systems mainly including the nervous system and internal organs. A consequent screening and timely preventive treatment of lesions are crucial for patients affected by VHL disease. Surgical indications and treatment have been evaluated and optimized over many years. In the last decade, pharmacological therapies have been evolving, but are largely still at an experimental stage. Effective pharmacological therapy as well as detection of biomarkers is based on the understanding of the molecular basis of disease. The molecular basis of von Hippel-Lindau disease is the loss of function of the VHL protein and subsequent accumulation of hypoxia-inducible factor with downstream effects on cellular metabolism and differentiation. Organs affected by VHL disease may develop frank tumors. More characteristically, however, they reveal multiple separate microscopic foci of neoplastic cell proliferation. The exact mechanisms of tumorigenesis in VHL disease are, however, still not entirely understood and knowledge on biomarkers and targeted therapy is scarce.

show abstract

“…Combination therapy, such as that for the small retinal hemangioblastoma in von Hippel-Lindau disease, is probably one of the best treatment choices for VPT. 19 Two of our cases had VT and tumor resection to remove the tumor and ERM at the same time. One had PDT plus IVI of ranibizumab before the surgery in attempt to decrease the tumor size.…”

Section: Discussionmentioning

confidence: 87%

Clinical characters and treatments of retinal vasoproliferative tumors

Huang

Chen

2016

Taiwan Journal of Ophthalmology

Self Cite

View full text Add to dashboard Cite

Retinal vasoproliferative tumors (VPT) are uncommon benign vascular tumors. They mostly occur in healthy patients, but may be associated with other chorioretinal diseases. Here we report four patients with VPT at a referral center from 2006 to 2015. Three patients denied any past history and one had a history of retinal detachment surgery. VPT-related complications included epiretinal membrane (ERM) (n = 2), cystoids macular edema (n = 1), and lamellar hole combined with dense cataract, rigid anterior capsule and vitreous opacity (n = 1). Treatments for VPT and comorbidities included vitrectomy (VT) and membrane peeling with tumor resection (n = 2), a combined treatment of photodynamic therapy (PDT) and intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) (n = 2). Tumor shrinkage was achieved in both patients treated with PDT and IVI of anti-VEGF injection. The other two patients with ERM were successfully treated with VT and tumor resection. Visual acuity improved at least two lines in three patients, and one patient had decreased vision due to cataract formation after VT. Pathology of the resected tumor in one case revealed massive gliosis with positive stain of vascular endothelial cells and glial fibrillary acidic protein stain. Yet the peeled membrane was acellular. Possible beneficial treatments for VPT and comorbidities include PDT combined with IVI of anti-VEGF, or VT and membrane peeling with tumor resection.

show abstract

Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel–Lindau disease

Cited by 14 publications

References 18 publications

Clinical use of photodynamic therapy in ocular tumors

Clinical use of photodynamic therapy in ocular tumors

<p>Von Hippel-Lindau Disease: Current Challenges and Future Prospects</p>

Clinical characters and treatments of retinal vasoproliferative tumors

Contact Info

Product

Resources

About